Micro-RNAs Predict Response to Systemic Treatments in Metastatic Renal Cell Carcinoma Patients: Results from a Systematic Review of the Literature
Locally advanced or metastatic renal cell carcinomas (mRCCs) account for up to 15% of all kidney cancer diagnoses. Systemic therapies (with or without surgery) represent gold standard treatments, mostly based on tyrosine kinase inhibitors in association with immunotherapy. We provide an overview of...
Збережено в:
| Автори: | , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
MDPI AG
2022-05-01
|
| Серія: | Biomedicines |
| Предмети: | |
| Онлайн доступ: | https://www.mdpi.com/2227-9059/10/6/1287 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|